Home » Emergent Bio buys anthrax biologic raxibacumab from Glaxo for up to $96M – Emergent BioSolutions Inc. (NYSE:EBS) | Seeking Alpha
Emergent Biosystems (NYSE:EBS) inks an agreement with GlaxoSmithKline (NYSE:GSK) to acquire raxibacumab, a fully human monoclonal antibody for the treatment and prevention of inhaled anthrax, for $76M in upfront cash and up to $20M in milestones.